Trial Profile
A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
- Indications Colorectal cancer; Haematological malignancies; Liposarcoma; Merkel cell carcinoma; Peripheral T-cell lymphoma; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms All-comers
- Sponsors Aileron Therapeutics
- 22 Jul 2021 Results published in the Clinical Cancer Research
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.
- 09 Jan 2020 Status changed from recruiting to active, no longer recruiting.